Axsome Therapeutics (AXSM) PT Raised to $196 at Morgan Stanley
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall St futures jump as Democrats sweep midterms
- CVS Health plans to split into two public companies by 2028
- UBS starts bullish coverage on Ferrari Group on luxury logistics growth
- Citi cuts Adobe rating on ’rising risk of a hard reset’
- Apple shares slip amid guidance for tightening margins, slowing services growth
Tweet
Share
E-mailGet Alerts AXSM Hot Sheet
Price: $139.61 --0%
Rating Summary:
27 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 15 | Down: 20 | New: 12
Rating Summary:
27 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 15 | Down: 20 | New: 12
Join SI Premium – FREE
Morgan Stanley analyst Sean Laaman raised the price target on Axsome Therapeutics (NASDAQ: AXSM) to $196.00 (from $194.00) while maintaining a Overweight rating.
You May Also Be Interested In
- Axsome Therapeutics (AXSM) PT Lowered to $250 at Guggenheim
- Axsome Therapeutics (AXSM) PT Lowered to $272 at Mizuho
- Fortis (FTS:CN) (FTS) PT Raised to Cdn$90 at Desjardins
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
